MedTrace Logo

A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage

NCT03189069 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36000

Last updated 2019-01-30

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the risk of major bleeding and stroke/systemic embolism (SE) among novel oral anti-coagulant (OAC) naïve and warfarin naïve Medicare Advantage patients with non-valvular atrial fibrillation (NVAF) treated with apixaban, dabigatran, rivaroxaban, or warfarin.

Conditions

Interventions

DRUG

Apixaban

Treatment for NVAF patients

DRUG

Dabigatran

Treatment for NVAF patients

DRUG

Rivaroxaban

Treatment for NVAF patients

DRUG

Warfarin

Treatment for NVAF patients

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-06
Primary Completion
2017-05-31
Completion
2017-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03189069 on ClinicalTrials.gov